ACE inhibitors: back to prime time?
作者信息
Gupta Milan, Verma Subodh, Mancini G B John
出版信息
Heart. 2007 Sep;93(9):1015-6. doi: 10.1136/hrt.2006.108100.
Abstract
摘要
相似文献
1
ACE inhibitors: back to prime time?血管紧张素转换酶抑制剂：重回黄金时代？
Heart. 2007 Sep;93(9):1015-6. doi: 10.1136/hrt.2006.108100.
2
Merck Serono targets convenient, affordable medicines for patients at risk.默克雪兰诺致力于为有患病风险的患者提供便捷且价格合理的药物。
Cardiovasc J Afr. 2009 Jan-Feb;20(1):77.
3
Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?无症状外周动脉疾病：心血管风险的药物预防是否具有成本效益？
Eur J Cardiovasc Prev Rehabil. 2011 Apr;18(2):254-61. doi: 10.1177/1741826710389368. Epub 2011 Jan 28.
4
[Secondary prevention after cardiac infarct; therapeutic efficiency--cost-benefit ratio].[心肌梗死后的二级预防；治疗效果——成本效益比]
Internist (Berl). 2001 May;42(5):713-9. doi: 10.1007/s001080050812.
5
ACE inhibitors--revisited.血管紧张素转换酶抑制剂——再探讨
J Assoc Physicians India. 2000 Jul;48(7):715-8.
6
[Cardiovascular pharmacotherapy in old age: How beneficial is it? What does it cost?].[老年心血管药物治疗：益处有多大？成本几何？]
Praxis (Bern 1994). 1995 Oct 31;84(44):1248-51.
7
Angiotensin converting enzyme inhibition in cardiovascular risk populations: a practical approach to identify the patient who will benefit most.心血管风险人群中的血管紧张素转换酶抑制：一种识别最能获益患者的实用方法。
Curr Opin Cardiol. 2007 Jul;22(4):267-72. doi: 10.1097/HCO.0b013e3281a7ec81.
8
Underuse of evidence-based therapies.循证疗法的使用不足。
Circulation. 2004 Aug 10;110(6):644-5. doi: 10.1161/01.CIR.0000139762.65274.7D.
9
Question: does isosorbide dinitrate/hydralazine therapy benefit systolic heart failure patients with renal insufficiency?问题：硝酸异山梨酯/肼屈嗪疗法对肾功能不全的收缩性心力衰竭患者有益吗？
J Okla State Med Assoc. 2011 Feb;104(2):49-50.
10
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of economic models in randomized clinical trials.评估心血管治疗价值中的经济学与成本效益。经济模型在随机临床试验中的作用。
Am Heart J. 1999 May;137(5):S41-6. doi: 10.1016/s0002-8703(99)70427-8.
本文引用的文献
1
Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study.利用EUROPA研究的数据评估培哚普利在降低稳定型冠状动脉疾病患者心血管事件方面的成本效益。
Heart. 2007 Sep;93(9):1081-6. doi: 10.1136/hrt.2005.086728. Epub 2006 Nov 29.
2
Effect of ramipril on the incidence of diabetes.雷米普利对糖尿病发病率的影响。
N Engl J Med. 2006 Oct 12;355(15):1551-62. doi: 10.1056/NEJMoa065061. Epub 2006 Sep 15.
3
Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials.血管紧张素转换酶抑制剂用于无左心室收缩功能障碍或心力衰竭的稳定型血管疾病：三项试验的联合分析
Lancet. 2006 Aug 12;368(9535):581-8. doi: 10.1016/S0140-6736(06)69201-5.
4
Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial.血管紧张素转换酶抑制剂治疗对慢性稳定型冠心病患者肾功能及疗效的影响：预防事件用ACE抑制剂（PEACE）试验
Circulation. 2006 Jul 4;114(1):26-31. doi: 10.1161/CIRCULATIONAHA.105.592733. Epub 2006 Jun 26.
5
Angiotensin-converting enzyme inhibition in patients with coronary artery disease and preserved left ventricular function Ischemia Management with Accupril post-bypass graft via inhibition of angiotensin-converting enzyme (IMAGINE) compared with the other major trials in coronary artery disease.冠状动脉疾病且左心室功能保留患者的血管紧张素转换酶抑制作用：与冠状动脉疾病的其他主要试验相比，通过抑制血管紧张素转换酶进行搭桥术后阿库普利缺血管理（IMAGINE）
Am Heart J. 2006 Jun;151(6):1240-6. doi: 10.1016/j.ahj.2005.07.010.
6
Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk.培哚普利对不同风险水平的稳定型冠心病患者的治疗获益。
Eur Heart J. 2006 Apr;27(7):796-801. doi: 10.1093/eurheartj/ehi809. Epub 2006 Feb 23.
7
Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension.雷米普利对心血管事件及糖尿病的长期影响：心脏结局预防评估（HOPE）研究扩展的结果
Circulation. 2005 Aug 30;112(9):1339-46. doi: 10.1161/CIRCULATIONAHA.105.548461.
8
Angiotensin-converting-enzyme inhibition in stable coronary artery disease.稳定型冠状动脉疾病中的血管紧张素转换酶抑制作用
N Engl J Med. 2004 Nov 11;351(20):2058-68. doi: 10.1056/NEJMoa042739. Epub 2004 Nov 7.
9
National Institute for Clinical Excellence and its value judgments.国家临床优化研究所及其价值判断。
BMJ. 2004 Jul 24;329(7459):224-7. doi: 10.1136/bmj.329.7459.224.
10
Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).培哚普利对稳定型冠心病患者心血管事件的降低疗效：随机、双盲、安慰剂对照、多中心试验（EUROPA研究）
Lancet. 2003 Sep 6;362(9386):782-8. doi: 10.1016/s0140-6736(03)14286-9.
Zotero 插件